BioAgilytix names Dr. Linda Robbie as Chief Operating Officer

BioAgilytix Labs, a CRO supporting pharmaceutical and biotech partners in all phases of drug development, has announced the appointment of Dr. Linda Robbie as Chief Operating Officer.

For the past three years, Dr. Robbie has served as Vice President and General Manager of Boston operations, responsible for leading all Bioanalytical Services at BioAgilytix’s Boston, MA Laboratory. During this time, she directed all initiatives relating to science, technology, and laboratory operations.

Dr. Robbie has more than 25 years of experience with biomarker assay technologies, including 20 years of experience in scientific leadership positions. She was previously Senior Vice President of Science and Laboratory Operations at Cambridge Biomedical and joined BioAgilytix’s leadership team when the company was acquired in November 2019. She has also held senior roles with Quintiles and Immucor.

Dr. Robbie replaces Dr. Michael, who will be leaving the company at the end of the month.

With laboratory locations in North Carolina’s Research Triangle Park; Cambridge, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of therapeutics across several industries and disease states. It offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product release testing, stability testing, etc.) BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory.